Document:

<PAGE>   1

                                                                    EXHIBIT 10.9

                         ZFP MATERIAL TRANSFER AGREEMENT

        THIS ZFP CUSTOM SYNTHESIS AGREEMENT (the "Agreement") dated as of March
8, 1999 ("Effective Date"), is entered into between SANGAMO BIOSCIENCES, INC., a
Delaware corporation ("Sangamo"), having a place of business at Point Richmond
Tech Center, 501 Canal Boulevard, Suite A100, Richmond, California 94804, and
Japan Tobacco Inc., a Japanese corporation (the "Customer"), having a place of
business at    *     *     *     *     *     *     *     *     *     *.

        WHEREAS, Sangamo has rights and expertise regarding the design and
synthesis of certain zinc finger DNA recognition proteins and genes encoding
such proteins.

        WHEREAS, the Customer desires to have Sangamo design, assemble,
characterize and deliver to Customer certain of these materials solely for the
Customer's own internal research (except as otherwise expressly provided herein)
and preclinical development purposes on the terms and conditions set forth in
this Agreement.

        NOW, THEREFORE, in consideration of the foregoing premises and the
mutual covenants set forth below, the parties agree as follows:

        I. Definitions. For purposes of this Agreement, the terms defined in
this Section 1 shall have the respective meanings set forth below:

               1.1 "Affiliate" shall mean, with respect to any Person, any other
Person which directly or indirectly controls, is controlled by, or is under
common control with, such Person. A Person shall be in control of another Person
if it owns, or directly or indirectly controls, at least fifty percent (50%) of
the voting stock or other ownership interest of the other Person, or if it
directly or indirectly possesses the power to direct or cause the direction of
the management and policies of the other Person by any means. Notwithstanding
the foregoing, the government of Japan shall not be deemed an Affiliate.

               1.2 "Confidential Information" shall mean, with respect to a
party, all information (and all tangible and intangible embodiments thereof)
which is disclosed by such party to the other party and is marked as
"Confidential" by each party, identified as or otherwise acknowledged to be
confidential at the time of disclosure to the other party. Each party shall also
confirm in writing within thirty (30) days any Confidential Information that it
discloses orally. Notwithstanding the foregoing, Confidential Information of a
party shall not include information which the other party can establish by
written documentation (a) to have been publicly known prior to disclosure of
such information by the disclosing party to the other party, (b) to have become
publicly known, without the fault of the other party, subsequent to disclosure
of such information by the disclosing party to the other party, (c) to have been
received by the other party at any time from a source, other than the disclosing
party, rightfully having possession of and the right to disclose such
information, (d) to have been otherwise known by the other party prior to
disclosure of such information by the disclosing party to the other party, or
(e) to have been

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.
<PAGE>   2

independently developed by employees or agents of the other party without access
to or use of such information disclosed by the disclosing party to the other
party.

               1.3 "Derivative" shall mean any protein or conjugate (including a
conjugate to a functional domain other than the Functional Domain) derived from
a ZFP, provided that the contiguous amino acid sequence of such ZFP has not been
altered, and the amino acid sequence of such protein or conjugate, except for
progeny.

               1.4 "Functional Domain" shall mean the functional domain set
forth on Schedule A, to which each ZFP shall be conjugated by Sangamo hereunder.

               1.5 "Genetic Material" shall mean, with respect to any ZFP or
Derivative, the nucleotide sequence encoding such ZFP or Derivative and all
fragments of such gene sequence.

               1.6 "Person" shall mean an individual, corporation, partnership,
limited liability company, trust, business trust, association, joint stock
company, joint venture, pool, syndicate, sole proprietorship, unincorporated
organization, governmental authority or any other form of entity not
specifically listed herein.

               1.7 "Progeny" shall mean any biological progeny which contains
the ZFP Materials originated by the Customer including but not limited to cells
and animals.

               1.8 "Research Field" shall mean the research and preclinical
development of products and services for use in the diagnosis, prevention or
treatment of any disease, state or condition in humans (excluding the sale or
provision of, to any third parties, products and services that incorporate,
contain or use zinc finger DNA recognition proteins, genes that encode such
proteins, or fragments or derivatives of such proteins or genes).

               1.9 "Target(s)" shall mean the nucleotide sequence(s) set forth
on Schedule A.

               1.10 "ZFP" shall mean a zinc finger DNA recognition protein
binding to the Target which is designed by Sangamo and for which the Genetic
Material is delivered to the Customer hereunder, and the amino acid sequence of
such protein.

               1.11 "ZFP Materials" shall mean, collectively, the ZFPs, any
Derivatives, the Genetic Materials which encode any ZFP or Derivative, and all
fragments and derivatives of the foregoing.

        2. Design and Delivery of ZFP Materials.

               2.1 Promptly after the date of this Agreement, the Customer shall
deliver to Sangamo the nucleotide sequence for  *  Target(s) and such other
information as the parties mutually agree is reasonably necessary to assist
Sangamo in designing the ZFPs. Notwithstanding the foregoing, the Customer shall
have final discretion with respect to the provision of such information.

               2.2 Sangamo shall design, assemble and characterize two (2) zinc
finger DNA recognition proteins binding to each Target.
<PAGE>   3

               2.3 Within *  weeks after receipt of the information described in
Section 2.1 above, Sangamo shall deliver to the Customer certain information
regarding the characterization of each ZFP (including data and specifications
regarding the binding sites, affinities, and in vivo co-transfection reporter
activation assays) that is reasonably necessary for the Customer to use the ZFP
Materials in the Research Field. Sangamo will consult by telephone or facsimile
or visits at mutually agreeable times at no additional cost to Customer with
Customer's employees to answer questions related to the ZFP Materials.

               2.4 Within      *      days after delivery of the   *   Target to
Sangamo, the Customer shall pay Sangamo      *     *     *     *     *     *
   *      Within     *     * days after delivery of the second Target to
Sangamo, the Customer shall pay Sangamo      *     *     *     *     *     *
Such payment shall be in United States Dollars in immediately available funds
and shall be made by wire transfer from a United States bank located in the
United States to such bank account as designated by Sangamo to the Customer.

                      Within      *     *     days after the Customer receives
the materials and information described in Section 2.3 above, the Customer shall
make diligent and good faith efforts to confirm the activity of the relevant
Target ZFPs in the same assays that Sangamo has used pursuant to section 2.3.
The Customer shall then pay Sangamo      *     *     *     *     *     *
for the first Target   *     *     *     *     *     *     *     *     *     *
     *     *     *     *     *     *     *     *     *     *     *     *     *
for the second Target. If the Customer is unable to confirm the activity of a
ZFP in the same assays as used by Sangamo, then Sangamo, shall redesign and
deliver redesigned ZFP Materials to the Customer within 8 weeks after the
Customer so notifies Sangamo. In the event that the Customer is unable to
confirm activity of the re-designed ZFP Materials then the Customer shall have
no obligation to make any additional payments. Payment shall be in United States
Dollars in immediately available funds and shall be made by wire transfer from a
United States bank located in the United States to such bank account as
designated by Sangamo to the Customer.

                      Sangamo shall issue signed invoices in advance for each
payment due hereunder. Withholding tax shall be deducted from the payments made
by the Customer to the proper tax authority and a receipt of payments of the tax
secured and promptly delivered to Sangamo.

               2.5 In connection with the shipping of Materials, Sangamo agrees
to pay for all shipping, handling, and customs duty related costs.

        3. Use of ZFP Materials.

               3.1 The Customer shall use the ZFP Materials (and all results of
its activities in the Research Field hereunder) solely in the Research Field,
and not for any other purpose.

               3.2 The Customer shall not alter the nucleotide sequence or amino
acid sequence of, or reverse engineer, the ZFP Materials; provided, however,
that the Customer may make Derivatives of the ZFPs.

               3.3 The Customer shall use the ZFP Materials under commercially
and scientifically reasonable containment conditions. The Customer shall not
transfer or provide access to the ZFP Materials to any other Person.
Notwithstanding the foregoing, the Customer

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.
<PAGE>   4

may transfer the ZFP Materials to an Affiliate (without the further right to
transfer), provided (a) the Customer shall give prior express written notice
thereof to Sangamo, and (b) such Affiliate agrees to be bound by the terms and
conditions set forth in this Agreement binding on the Customer. The Customer may
also transfer ZFP Materials to its research partners without any additional
charges or fees, subject to agreement by such partners of the terms and
conditions set forth in this Agreement and with the prior written consent of
Sangamo, such consent not to be unreasonably withheld. The Customer shall limit
access to the ZFP Materials to those of its employees and consultants working on
its premises to the extent such access is reasonably necessary to the conduct of
its activities in the Research Field.

               3.4 The Customer shall not (and shall not attempt or purport to)
sell, license or otherwise transfer title to or an interest in, or otherwise
commercially use the ZFP Materials without the prior express written consent of
Sangamo.

               3.5 The Customer acknowledges that the ZFP Materials are
experimental in nature, may have unknown characteristics and have not been
approved for use in humans. The Customer shall use prudence and reasonable care
in the use, handling, storage, transportation, disposition and containment of
the ZFP Materials, and shall comply with all applicable laws, regulations and
guidelines applicable to the ZFP Materials or the use thereof and with any
safety precautions accompanying the ZFP Materials. The Customer shall not (and
shall not attempt or purport to) administer the ZFP Materials to humans, or file
or submit any regulatory application or other submission to obtain approval
therefor.

        4. Non-Assertion. Neither the Customer nor its Affiliates (nor their
respective successors, assigns, licensees or other transferees) shall enforce
(or attempt or purport to enforce) against Sangamo or its Affiliates, licensees
(of rights in zinc finger DNA recognition proteins) or manufacturers,
distributors or other purchasers (of zinc finger DNA recognition proteins) any
patent that claims zinc finger DNA recognition proteins, Genetic Materials
encoding such proteins, fragments of such proteins or Genetic Materials, or the
use of any of the foregoing, subject, expressly, to section 10.

        5. No Prohibition on Sangamo. Nothing in this Agreement shall prohibit
Sangamo from making, using, offering for sale, selling to others or importing
zinc finger DNA recognition proteins, genetic materials encoding such proteins,
fragments of such proteins or genetic materials or from licensing others to do
the same; provided, however, that Sangamo shall not design, assemble,
characterize and deliver to any other Person any zinc finger DNA recognition
protein binding to the Target (or genetic material encoding such protein) in
less time than the time frame published by Sangamo      *       for its custom
design, assembly, characterization and delivery of a zinc finger DNA recognition
protein (or genetic material encoding such protein) generally.

             *

               THE CUSTOMER ACKNOWLEDGES THAT THE ZFP MATERIALS ARE PROVIDED "AS
IS" AND THAT SANGAMO MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS
FOR ANY PARTICULAR PURPOSE OR NONINFRINGEMENT OF THE PATENT RIGHTS OR OTHER
INTELLECTUAL PROPERTY RIGHTS OF ANY OTHER PERSON.

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.

<PAGE>   5

                    *
     *     *     *     *     *     *     *     *     *     *     *     *     *
     *     *     *     *     *     *     *     *     *     *     *     *     *

                    *
     *     *     *     *     *     *     *     *     *     *     *     *     *
     *     *     *     *     *     *     *     *     *     *     *     *     *

        7. Confidentiality.

               7.1 For a period of five (5) years following the date of this
Agreement, subject to the Confidential Disclosure Agreement between Sangamo and
the Customer as of March 8, 1999, and January 12, 1999, each party shall
maintain in confidence all Confidential Information disclosed by the other
party, and shall not use, disclose or grant the use of the Confidential
Information except on a need-to-know basis to its directors, officers, employees
and consultants to the extent such disclosure is reasonably necessary in
connection with such party's activities expressly authorized by this Agreement
and ordinary business operations. Each party shall notify the other promptly
upon discovery of any unauthorized use or disclosure of the other party's
Confidential Information.

               7.2 Sangamo shall not disclose the identity of the Target and the
information relating to the Target to any other Person without the prior consent
of the Customer. Neither party shall disclose any terms or conditions set forth
in this Agreement to any other Person without the prior consent of the other
party; provided, however, that a party may disclose the terms or conditions set
forth in this Agreement, (a) on a need-to-know basis to its legal and financial
advisors to the extent such disclosure is reasonably necessary in connection
with such party's activities as expressly permitted by this Agreement, and (b)
to a third party in connection with (i) an equity investment in such party, (ii)
a merger, consolidation or similar transaction by such party, or (iii) the sale
of all or substantially all of the assets of such party.

               7.3 The confidentiality obligations contained in this Section 7
shall not apply to the extent information is required to be disclosed to a
governmental agency or is necessary to file or prosecute patent applications or
to the extent that a party is required to disclose information by applicable
law, regulation or order of a court of competent jurisdiction, provided that
such party shall provide written notice to the other party and sufficient
opportunity to object to any such disclosure or to request confidential
treatment. The Customer may disclose Confidential Information of Sangamo
relating to the results of the Customer's research and evaluation hereunder to
any Affiliate.

               7.4 To the extent that a party is authorized by this Agreement to
disclose Confidential Information of the other party to any other Person, prior
to disclosure, such party shall obtain agreement of any such Person to hold in
confidence and not use the Confidential Information of the other party for any
purpose other than those permitted by this Agreement.

        8. Indemnification and Insurance.

               8.1 The Customer shall indemnify and hold harmless Sangamo from
and against all losses, liabilities, damages and expenses (including reasonable
attorneys' fees and costs) resulting from all claims, demands, actions and other
proceedings by any other Person to

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.

<PAGE>   6
the extent arising from (a) the use by Sangamo of the Target under this
Agreement, unless due to reasons relating to Sangamo's ZFP Materials, (b) the
breach by the Customer of any covenant under this Agreement, or (c) the use by
the Customer or its Affiliates of the ZFP Materials or the results of their
respective activities hereunder, except in each case to the extent any such
loss, liability, damage or expense results from the negligence or willful
misconduct of Sangamo.

               8.2 EXCEPT AS OTHERWISE SET FORTH IN THIS SECTION 8, IN NO EVENT
SHALL EITHER PARTY BE LIABLE FOR LOSS OF PROFITS OR INCIDENTAL, SPECIAL,
CONSEQUENTIAL OR PUNITIVE DAMAGES OF THE OTHER PARTY DIRECTLY OR INDIRECTLY
ARISING OUT OF THIS AGREEMENT.

        9. Miscellaneous.

               9.1 This Agreement shall be governed by and construed in
accordance with the laws of the State of California, without regard to the
conflicts of law principles thereof.

               9.2 This Agreement does not grant to the Customer any license or
other right in the patent rights or other intellectual property rights of
Sangamo except and only to the extent necessary to enable the Customer to
conduct its internal research and preclinical development permitted hereby.

               9.3 For the period from the date of this Agreement through the
date that is one (1) year after the date Sangamo delivers to the Customer the
ZFP Materials and information under Section 2.3 above, neither the Customer nor
its Affiliates shall directly or indirectly solicit or in any manner encourage
any employee of Sangamo to leave its employ.

               9.4 Neither party shall assign or otherwise transfer (whether
voluntarily, by operation of law or otherwise) this Agreement or any right or
obligation hereunder, without the prior express written consent of the other;
provided, however, that either party may, without such consent, assign this
Agreement and its rights and obligations hereunder in connection with the
transfer or sale of all or substantially all of its business, or in the event of
its merger, consolidation, change in control or similar transaction. Any
permitted assignee shall assume all obligations of its assignor under this
Agreement. Any purported assignment or transfer in violation of this Section 9.4
shall be void.

               9.5 This Agreement contains the entire understanding of the
parties regarding the subject matter hereof. All express or implied
representations, agreements and understandings, either oral or written,
heretofore made are expressly superseded by this Agreement.

       10. Ownership. All data and results of experiments obtained by the
Customer through the use of the ZFP Materials (the "Results") and inventions
from the use of the ZFP Materials shall be exclusively owned by the Customer and
the Customer shall have the right to use them for whatever purposes as it
desires, provided, however, that the use of the Progeny shall be limited to the
Research Field. For the avoidance of doubt, Sangamo shall not have the right to
use, commercialize, or otherwise exploit for whatever purpose the Results or any
of the Customer's inventions from the use of the ZFP Materials.

       11. Publication. Customer may publish the Results at its sole discretion
provided

<PAGE>   7

that Sangamo Confidential Information shall be removed from such publications
or written permission obtained from Sangamo prior to the use of such
Information, such permission not to be unreasonably withheld.

        12. Term and Termination

               12.1 This Agreement shall commence on the Effective Date and
unless sooner terminated as provided below, shall remain until the conclusion of
the evaluation stated in Section 3. At the conclusion of this term, this
Agreement may be amended or extended by mutual written consent of the parties.

               12.2 Upon termination of this Agreement, for any reason, Customer
shall return or destroy all unused Genetic Materials to Sangamo if so requested
by Sangamo, and shall provide written certification within thirty (30) days in
case of such destruction.

               12.3 The provisions of Sections 4, 6, 7, 8, 9, 10, and 11 shall
survive any termination of this Agreement.

        IN WITNESS WHEREOF, the parties have entered into the Agreement
effective as of the date first written above.

                                        SANGAMO BIOSCIENCES, INC.

                                        By:

                                        Title:

                                        JAPAN TOBACCO INC.

                                        By:

                                        Title:

<PAGE>   8

                                [JT LETTERHEAD]

June 18, 1999

Sangamo BioSciences, Inc.
Point Richmond Tech Center II
501 Canal Blvd., Suite A 100
Richmond, CA 94804

Attention: Dr. Eric Rhodes
           Director, Commercial Development

RE:        Amendment of ZFP Material Transfer Agreement dated March 9, 1999.

Gentlemen:

The purpose of this letter is to hereby confirm our mutual understanding that,
with respect to the March 9, 1999 ZFP Material Transfer Agreement, as set forth
below;

1. Section 7.1 shall be amended as follows:

   "For a period of five (5) years following the date of this Agreement, subject
   to the Confidential Disclosure Agreements between Sangamo and the Customer as
   of June 15, 1999, and March 8, 1999 and January 12, 1999, each party shall
   maintain in confidence all Confidential Information disclosed by the other
   party, and shall not use, disclose or grant the use of the Confidential
   Information except on a need-to-know basis to its directors, officers,
   employees and consultants to the extent such disclosure is reasonably
   necessary in connection with such party's activities expressly authorized by
   this Agreement and ordinary business operations. Each party shall notify the
   other promptly upon discovery of any unauthorized use or disclosure of the
   other party's Confidential Information."

2. Schedule A shall be amended as set forth in the attachment hereto.

Please confirm your acknowledgement of and agreement with the above, by duly
signing and dating in the spaces provided below.

Sincerely yours,

/s/     *
-----------------------------
        *
Vice President

Sangamo BioSciences Inc.

By:  /s/ PETER BLUFORD
    --------------------------------

Name: Peter Bluford

Title: VP, Corp. Div.

Date: 7-1-99

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.<PAGE>   1

                                                                  EXHIBIT 10.12

                     MASSACHUSETTS INSTITUTE OF TECHNOLOGY

                                      and

                            SANGAMO BIOSCIENCES,INC.

                            PATENT LICENSE AGREEMENT
<PAGE>   2
11-7-94                                         TLO: LLN:jbw.sangamo.lic.ag41796
Patent Exclusive                                                  April 17, 1996

<TABLE>
<CAPTION>
                               TABLE OF CONTENTS

     <S>                                                               <C>
     WITNESSETH ......................................................  1

     1  DEFINITIONS ..................................................  2

     2  GRANT ........................................................  3

     3  DILIGENCE ....................................................  4

     4  ROYALTIES ....................................................  5

     5  REPORTS AND RECORDS ..........................................  6

     6  PATENT PROSECUTION ...........................................  7

     7  INFRINGEMENT .................................................  8

     8  PRODUCT LIABILITY ............................................  9

     9  EXPORT CONTROLS .............................................. 10

     10 NON-USE OF NAMES ............................................. 10

     11 ASSIGNMENT ................................................... 10

     12 DISPUTE RESOLUTION ........................................... 10

     13 TERMINATION .................................................. 11

     14 PAYMENTS, NOTICES AND OTHER COMMUNICATIONS ................... 12

     15 MISCELLANEOUS PROVISIONS ..................................... 13

     APPENDIX A ...................................................... 14
</TABLE>
<PAGE>   3

                     MASSACHUSETTS INSTITUTE OF TECHNOLOGY

                                      and

                           SANGAMO BIOSCIENCES, INC.

                            PATENT LICENSE AGREEMENT

     This Agreement is made and entered into this 9 day of MAY, 1996, (the
"EFFECTIVE DATE") by and between the MASSACHUSETTS INSTITUTE OF TECHNOLOGY, a
corporation duly organized and existing under the laws of the Commonwealth of
Massachusetts and having its principal office at 77 Massachusetts Avenue,
Cambridge, Massachusetts 02139, U.S.A. (hereinafter referred to as "M.I.T."),
and Sangamo BioSciences, Inc. a corporation duly organized under the laws of
DELAWARE and having its principal office at 950 MARINA VILLAGE PKWY, SUITE 100,
ALAMEDA, CA 94501 (hereinafter referred to as "LICENSEE").

                                   WITNESSETH

     WHEREAS, M.I.T. is the owner of certain PATENT RIGHTS (as later defined
herein) relating to M.I.T. Case No. 6929, "Zinc Finger Proteins With High
Affinity New DNA Binding Specificities" by Carl O. Pabo and Edward J. Rebar and
has the right to grant licenses under said PATENT RIGHTS, subject only to a
royalty-free, nonexclusive license heretofore granted to the United States
Government;

     WHEREAS, M.I.T. desires to have the PATENT RIGHTS developed and
commercialized to benefit the public and is willing to grant a license
thereunder;

     WHEREAS, LICENSEE has represented to M.I.T., to induce M.I.T. to enter
into this Agreement, that LICENSEE is experienced in the development,
production, manufacture, marketing and sale of products similar to the LICENSED
PRODUCT(s) (as later defined herein) and/or the use of the LICENSED
PROCESS(es) (as later defined herein) and that it shall commit itself to a
thorough, vigorous and diligent program of exploiting the PATENT RIGHTS so that
public utilization shall result therefrom; and

     WHEREAS, LICENSEE desires to obtain a license under the PATENT RIGHTS upon
the terms and conditions hereinafter set forth.

     NOW, THEREFORE, in consideration of the premises and the mutual covenants
contained herein, the parties hereto agree as follows:

                                      -1-

<PAGE>   4

                                1-DEFINITIONS

     For the purposes of this Agreement, the following words and phrases shall
have the the following meanings:

     1.1  "LICENSEE" shall include a related company of Sangamo BioSciences,
Inc. the voting stock of which is directly or indirectly at least Fifty Percent
(50%) owned or controlled by Sangamo BioSciences, Inc., an organization which
directly or indirectly controls more than Fifty Percent (50%) of the voting
stock of Sangamo BioSciences, Inc. and an organization, the majority ownership
of which is directly or indirectly common to the ownership of Sangamo
BioSciences, Inc.

     1.2  "PATENT RIGHTS" shall mean all of the following M.I.T. intellectual
property:

          a.   the United States patents listed in Appendix A;

          b.   the United States patent applications listed in Appendix A, and
               divisionals, continuations and claims of continuation-in-part
               applications which shall be directed to subject matter
               specifically described in such patent applications, and the
               resulting patents;

          c.   any patents resulting from reissues or reexaminations of the
               United States patents described in a. and b. above;

     1.3  A "LICENSED PRODUCT" shall mean any product or part thereof which:

          a.   is covered in whole or in part by an issued, unexpired claim or
               a pending claim contained in the PATENT RIGHTS in the country in
               which any such product or part thereof is made, used or sold; or

          b.   is manufactured by using a process or is employed to practice a
               process which is covered in whole or in part by an issued,
               unexpired claim or a pending claim contained in the PATENT
               RIGHTS in the country in which any LICENSED PROCESS is used or
               in which such product or part thereof is used or sold.

     1.4  A "LICENSED PROCESS" shall mean any process which is covered in whole
or in part by an issued, unexpired claim or a pending claim contained in the
PATENT RIGHTS.

     1.5 "NET SALES" shall mean LICENSEE's and its sublicensees' billings for
LICENSED PRODUCTS and LICENSED PROCESSES less the sum of the following:

          a.   discounts allowed in amounts customary in the trade for quantity
               purchases, cash payments, prompt payments, wholesalers and
               distributors;

          b.   sales, tariff duties and/or use taxes directly imposed and with
               reference to particular sales;

          c.   outbound transportation prepaid or allowed; and

          d.   amounts allowed or credited on returns.

                                      -2-

<PAGE>   5
     No deductions shall be made for commissions paid to individuals whether
they be with independent sales agencies or regularly employed by LICENSEE and
on its payroll, or for cost of collections. NET SALES shall occur when a
LICENSED PRODUCT or LICENSED PROCESS shall be invoiced. If a LICENSED PRODUCT
or LICENSED PROCESS shall be distributed or invoiced for a discounted price
substantially lower than customary in the trade or distributed at no cost to
affiliates or otherwise, NET SALES shall be based on the customary amount
billed for such LICENSED PRODUCTS or LICENSED PROCESSES.

     1.6  "TERRITORY" shall mean worldwide.

     1.7  "FIELDS OF USE" shall mean commercial research and development,
          manufacture, and sales of LICENSED PRODUCTS or LICENSED PROCESSES
          which contain, use or act on restriction enzymes and
          integrases/recombinases.

     Note: LICENSEE's rights to practice under the PATENT RIGHTS shall be in
     all FIELDS OF USE. The purpose of this FIELDS OF USE definition is to
     define the fields in which exclusivity is granted under this license under
     P. 2.3 below and in which LICENSEE may grant sublicenses under P. 2.6
     below.

                                   2 - GRANT

     2.1  M.I.T. hereby grants to LICENSEE the right and license in the
TERRITORY to practice under the PATENT RIGHTS and, to the extent not prohibited
by other patents, to make, have made, use, lease, sell and import LICENSED
PRODUCTS and to practice the LICENSED PROCESSES, until the expiration of the
last to expire of the PATENT RIGHTS, unless this Agreement shall be sooner
terminated according to the terms hereof.

     2.2  LICENSEE agrees that LICENSED PRODUCTS leased or sold in the United
States shall be manufactured  substantially in the United States.

     2.3  In order to establish exclusivity in the FIELDS OF USE for LICENSEE,
M.I.T. hereby agrees that it shall not grant any other license to make, have
made, use, lease, sell and import LICENSED PRODUCTS or to utilize LICENSED
PROCESSES subject to the royalty-free, nonexclusive license rights of the United
States Government per FAR 52.227-11, in the TERRITORY for the FIELDS OF USE.

     2.4  M.I.T. agrees that prior to granting a license to any third party
outside the defined FIELDS OF USE, it shall notify LICENSEE of its intent to
grant such a license and LICENSEE shall have sixty (60) days in which to
present to M.I.T. reasons for widening LICENSEE's exclusive FIELD OF USE beyond
that defined in P.1.7 above. M.I.T. shall consider granting such widening to
LICENSEE, for suitable consideration, depending upon LICENSEE's scientific
progress, development plans and financial resources to develop the widened
FIELD OF USE.

                                      -3-

<PAGE>   6
Any decision to widen the exclusive FIELD OF USE granted to LICENSEE shall be
at M.I.T.'s sole discretion.

     2.5 M.I.T. reserves the right to practice under the PATENT RIGHTS and to
allow third parties to practice under the PATENT RIGHTS in all fields of use
for noncommercial research purposes.

     2.6 LICENSEE shall have the right to enter into sublicensing agreements for
the rights, privileges and licenses granted hereunder only in the FIELDS OF USE.
Upon any termination of this Agreement, sublicensees' rights shall also
terminate, subject to Paragraph 13.6 hereof.

     2.7 LICENSEE agrees to incorporate Articles 2, 5, 7, 8, 9, 10, 12, 13 and
15 of this Agreement into its sublicense agreements, so that these Articles
shall be binding upon such sublicensees as if they were parties to this
Agreement.

     2.8 LICENSEE agrees to forward to M.I.T. a copy of any and all sublicense
agreements promptly upon execution by the parties.

     2.9 Nothing in this Agreement shall be construed to confer any rights upon
LICENSEE by implication, estoppel or otherwise as to any technology or patent
rights of M.I.T. or any other entity other than the PATENT RIGHTS, regardless
of whether such patent rights shall be dominant or subordinate to any PATENT
RIGHTS.

                                 3 - DILIGENCE

     3.1 LICENSEE shall use its best efforts to bring one or more LICENSED
PRODUCTS or LICENSED PROCESSES to market through a thorough, vigorous and
diligent program for exploitation of the PATENT RIGHTS and to continue active,
diligent marketing efforts for one or more LICENSED PRODUCTS or LICENSED
PROCESSES throughout the life of this Agreement.

     3.2 LICENSEE shall deliver to M.I.T. on or before December 31, 1996 a
business plan showing the amount of money, number and kind of personnel and
time budgeted and planned for each phase of development of the LICENSED
PRODUCTS and LICENSED PROCESSES and shall provide similar reports to M.I.T. on
or before December 31 of each year.

     3.3 LICENSEE's failure to perform in accordance with either Paragraph 3.1
or 3.2 above shall be grounds for M.I.T. to terminate this Agreement pursuant
to Paragraph 13.3 hereof.

                                 4 - ROYALTIES

     4.1 For the rights, privileges and license granted hereunder, LICENSEE
shall pay royalties to M.I.T. in the manner hereinafter provided to the end of
the term of the PATENT RIGHTS or until this Agreement shall be terminated:

                                      -4-
<PAGE>   7
       a.   License Issue Fee of                  *                 , which said
            License Issue Fee shall be deemed earned and due immediately upon
                    *        .

       b.   License Maintenance Fees of             *              *
                      per year payable on January 1, 1997 and on January 1 of
            each year thereafter; provided, however, License Maintenance Fees
            may be credited to Running Royalties subsequently due on NET SALES
            for each said year, if any. License Maintenance Fees paid in excess
            of Running Royalties shall not be creditable to Running Royalties
            for future years.

       c.   Running Royalties in an amount equal to           *           of NET
            SALES of the LICENSED PRODUCTS and LICENSED PROCESSES used, leased
            or sold by and/or for LICENSEE and/or its Sublicensees.

       d.   A milestone payment of                       *
                  *      upon                        *                        a
            LICENSED PRODUCT or LICENSED PROCESS in the FIELDS OF USE which
            falls under the claims of the PATENT RIGHTS.

       e.   A milestone payment of                 *                ) upon the
                                  *                       a LICENSED PRODUCT or
            LICENSED PROCESS outside the FIELDS OF USE which falls under the
            claims of the PATENT RIGHTS.

       f.   A milestone payment of                      *
            upon                           *                          a LICENSED
            PRODUCT or LICENSED PROCESS in the FIELDS OF USE which falls under
            the claims of the PATENT RIGHTS.

       g.   A milestone payment of                      *
            upon                          *                           a LICENSED
            PRODUCT or LICENSED PROCESS outside the FIELDS OF USE which falls
            under the claims of the PATENT RIGHTS.

       h.                 *                 per sublicense granted, plus * per
            year sublicense maintenance fees.

  4.2 All payments due hereunder shall be paid in full, without deduction of
taxes or other fees which may be imposed by any government, except as otherwise
provided in Paragraph 1.5(b).

   4.3 No multiple royalties shall be payable because any LICENSED PRODUCT, its
manufacture, use, lease or sale are or shall be covered by more than one PATENT
RIGHTS patent application or PATENT RIGHTS patent licensed under this Agreement.

  4.4 Royalty payments shall be paid in United States dollars in Cambridge,
Massachusetts, or at such other place as M.I.T. may reasonably designate
consistent with the laws and regulations controlling in any foreign country. If
any currency conversion shall be required in connection with the payment of
royalties hereunder, such conversion shall be made by using the exchange rate

                                      -5-

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.
<PAGE>   8
prevailing at the Chase Manhattan Bank (N.A.) on the last business day of the
calendar quarterly reporting period to which such royalty payments relate.

                            5 - REPORTS AND RECORDS

     5.1 LICENSEE shall keep full, true and accurate books of account
containing all particulars that may be necessary for the purpose of showing
the amounts payable to M.I.T. hereunder. Said books of account shall be kept at
LICENSEE's principal place of business or the principal place of business of the
appropriate division of LICENSEE to which this Agreement relates. Said books and
the supporting data shall be open at all reasonable times for five (5) years
following the end of the calendar year to which they pertain, to the inspection
of M.I.T. or its agents for the purpose of verifying LICENSEE's royalty
statement or compliance in other respects with this Agreement. Should such
inspection lead to the discovery of a greater than Ten Percent (10%) discrepancy
in reporting to M.I.T.'s detriment, LICENSEE agrees to pay the full cost of such
inspection.

     5.2 LICENSEE shall deliver to M.I.T. true and accurate reports, giving
such particulars of the business conducted by LICENSEE and its sublicensees
under this Agreement as shall be pertinent to diligence under Article 3 and
royalty accounting hereunder:

     a.   before the first commercial sale of a LICENSED PRODUCT or LICENSED
          PROCESS, annually, on January 31 of each year; and

     b.   after the first commercial sale of a LICENSED PRODUCT or LICENSED
          PROCESS, quarterly, within sixty (60) days after March 31, June 30,
          September 30 and December 31, of each year.

     These reports shall include at least the following:

     a.   number of LICENSED PRODUCTS manufactured, leased and sold by and/or
          for LICENSEE and all sublicensees;

     b.   accounting for all LICENSED PROCESSES used or sold by and/or for
          LICENSEE and all sublicensees;

     c.   accounting for NET SALES, noting the deductions applicable as provided
          in Paragraph 1.5;

     d.   Running Royalties due under Paragraph 4.1(c);

     e.   royalties due on other payments from sublicensees under paragraph
          4.1(d);

     f.   total royalties due; and

     g.   names and addresses of all sublicensees of LICENSEE.

     5.3 With each such report submitted, LICENSEE shall pay to M.I.T. the
royalties due and payable under this Agreement. If no royalties shall be due,
LICENSEE shall so report.

                                      -6-
<PAGE>   9
     5.4 On or before the ninetieth (90th) day following the close of
LICENSEE's fiscal year, LICENSEE shall provide M.I.T. with LICENSEE's certified
financial statements for the preceding fiscal year including, at a minimum, a
balance sheet and an income statement.

     5.5 The amounts due under Articles 4 and 6 shall, if overdue, bear
interest until payment at a per annum rate           *            the prime
rate in effect at the Chase Manhattan Bank (N.A.) on the due date. The
payment of such interest shall not foreclose M.I.T. from exercising any other
rights it may have as a consequence of the lateness of any payment.

                             6 - PATENT PROSECUTION

     6.1 M.I.T. shall apply for, seek prompt issuance of, and maintain the
PATENT RIGHTS during the term of this Agreement. The filing, prosecution and
maintenance of all PATENT RIGHTS applications and patents shall be the primary
responsibility of M.I.T.; provided, however, LICENSEE shall have reasonable
opportunities to advise M.I.T. and shall cooperate with M.I.T. in such filing,
prosecution and maintenance.

     6.2  Payment of all fees and costs relating to the filing, prosecution and
maintenance of the PATENT RIGHTS after the EFFECTIVE DATE shall be the
responsibility of LICENSEE, whether such fees and costs were incurred before or
after the EFFECTIVE DATE. LICENSEE shall pay such fees and costs to M.I.T.
within thirty (30) days of invoicing; late payments shall accrue interest and
shall be subject to Paragraph 5.5.

                                7 - INFRINGEMENT

     7.1  LICENSEE shall inform M.I.T. promptly in writing of any alleged
infringement of the PATENT RIGHTS by a third party and of any available
evidence thereof.

     7.2  M.I.T. shall have the right, but shall not be obligated, to prosecute
at its own expense all infringements of the PATENT RIGHTS and, in furtherance
of such right, LICENSEE hereby agrees that M.I.T. may include LICENSEE as a
party plaintiff in any such suit, without expense to LICENSEE. The total cost of
any such infringement action commenced or defended solely by M.I.T. shall be
borne by M.I.T., and M.I.T. shall keep any recovery or damages for past
infringement derived therefrom.

     7.3  If within six (6) months after having been notified of an alleged
infringement, M.I.T. shall have been unsuccessful in persuading the alleged
infringer to desist and shall not have brought and shall not be diligently
prosecuting an infringement action, or if M.I.T. shall notify LICENSEE at any
time prior thereto of its intention not to bring suit against any alleged
infringer in the TERRITORY for the FIELDS OF USE, then, and in those events
only, LICENSEE shall have the right, but shall not be obligated, to prosecute
at its own expense any infringement of the PATENT RIGHTS in the TERRITORY for
the FIELDS OF USE, and LICENSEE may, for such

                                      -7-

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.
<PAGE>   10
purposes, use the name of M.I.T. as party plaintiff; provided, however, that
such right to bring such an infringement action shall remain in effect only
during the EXCLUSIVE PERIOD. No settlement, consent judgment or other voluntary
final disposition of the suit may be entered into without the consent of
M.I.T., which consent shall not unreasonably be withheld. LICENSEE shall
indemnify M.I.T. against any order for costs that may be made against M.I.T. in
such proceedings.

     7.4 In the event that LICENSEE shall undertake litigation for the
enforcement of the PATENT RIGHTS, or the defense of the PATENT RIGHTS under
Paragraph 7.5, LICENSEE may withhold up to        *            of the payments
otherwise thereafter due M.I.T. under Article 4 hereunder and apply the same
toward reimbursement of up to  *   of LICENSEE's expenses, including reasonable
attorneys' fees, in connection therewith. Any recovery of damages by LICENSEE
for such suit shall be applied first in satisfaction of any unreimbursed
expenses and legal fees of LICENSEE relating to such suit, and next toward
reimbursement of M.I.T. for any payments under Article 4 past due or withheld
and applied pursuant to this Article 7. The balance remaining from any such
recovery shall be divided equally between LICENSEE and M.I.T.

     7.5 In the event that a declaratory judgment action alleging invalidity or
noninfringement of any of the PATENT RIGHTS shall be brought against M.I.T. or
LICENSEE, M.I.T., at its option, shall have the right, within thirty (30) days
after commencement of such action, to take over the sole defense of the action
at its own expense. If M.I.T. shall not exercise this right, LICENSEE may take
over the sole defense at LICENSEE's sole expense, subject to Paragraph 7.4.

     7.6 In any infringement suit as either party may institute to enforce the
PATENT RIGHTS pursuant to this Agreement, the other party hereto shall, at the
request and expense of the party initiating such suit, cooperate in all respects
and, to the extent possible, have its employees testify when requested and make
available relevant records, papers, information, samples, specimens, and the
like.

     7.7 LICENSEE shall have the sole right in accordance with the terms and
conditions herein to sublicense any alleged infringer in the TERRITORY for the
FIELDS OF USE for future use of the PATENT RIGHTS.

                             8 - PRODUCT LIABILITY

     8.1 LICENSEE shall at all times during the term of this Agreement and
thereafter, indemnify, defend and hold M.I.T., its trustees, directors,
officers, employees and affiliates,

                                      -8-

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.
<PAGE>   11
harmless against all claims, proceedings, demands and liabilities of any kind
whatsoever, including legal expenses and reasonable attorneys' fees, arising out
of the death of or injury to any person or persons or out of any damage to
property, resulting from the production, manufacture, sale, use, lease,
consumption or advertisement of the LICENSED PRODUCTS(s) and/or LICENSED
PROCESS(es) or arising from any obligation of LICENSEE hereunder.

     8.2  LICENSEE shall obtain and carry in full force and effect commercial,
general liability insurance which shall protect LICENSEE and M.I.T. with
respect to events covered by Paragraph 8.1 above. Such insurance shall be
written by a reputable insurance company authorized to do business in the
Commonwealth of Massachusetts, shall list M.I.T. as an additional named insured
thereunder, shall be endorsed to include product liability coverage and shall
require thirty (30) days written notice to be given to M.I.T. prior to any
cancellation or material change thereof. The limits of such insurance shall not
be less than One Million Dollars ($1,000,000) per occurrence with an aggregate
of Three Million Dollars ($3,000,000) for personal injury or death, and One
Million Dollars ($1,000,000) per occurrence with an aggregate of Three Million
Dollars ($3,000,000) for property damage. LICENSEE shall provide M.I.T. with
Certificates of Insurance evidencing the same.

     8.3  EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, M.I.T.,
ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES, AND AFFILIATES MAKE NO
REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS
FOR A PARTICULAR PURPOSE, VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING,
AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE.
NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR
WARRANTY GIVEN BY M.I.T. THAT THE PRACTICE BY LICENSEE OF THE LICENSE GRANTED
HEREUNDER SHALL NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD PARTY. IN NO EVENT
SHALL M.I.T., ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES BE
LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC
DAMAGE OR INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF WHETHER M.I.T.
SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE
POSSIBILITY OF THE FOREGOING.

                              9 - EXPORT CONTROLS

     LICENSEE acknowledges that it is subject to United States laws and
regulations controlling the export of technical data, computer software,
laboratory prototypes and other

                                      -9-
<PAGE>   12
commodities (including the Arms Export Control Act, as amended and the United
States Department of Commerce Export Administration Regulations). The transfer
of such items may require a license from the cognizant agency of the United
States Government and/or written assurances by LICENSEE that LICENSEE shall not
export data or commodities to certain foreign countries without prior approval
of such agency. M.I.T. neither represents that a license shall not be required
nor that, if required, it shall be issued.

                             10 - NON-USE OF NAMES

     LICENSEE shall not use the names or trademarks of the Massachusetts
Institute of Technology or Lincoln Laboratory, nor any adaptation thereof, nor
the names of any of their employees, in any advertising, promotional or sales
literature without prior written consent obtained from M.I.T., or said
employee, in each case, except that LICENSEE may state that it is licensed by
M.I.T. under one or more of the patents and/or applications comprising the
PATENT RIGHTS.

                               11 - ASSIGNMENT

     This Agreement is not assignable and any attempt to do so shall be void.

                           12 - DISPUTE RESOLUTION

     12.1  Except for the right of either party to apply to a court of
competent jurisdiction for a temporary restraining order, a preliminary
injunction, or other equitable relief to preserve the status quo or prevent
irreparable harm, any and all claims, disputes or controversies arising
under, out of, or in connection with the Agreement, including any dispute
relating to patent validity or infringement, which the parties shall be
unable to resolve within sixty (60) days shall be mediated in good faith. The
party raising such dispute shall promptly advise the other party of such
claim, dispute or controversy in a writing which describes in reasonable
detail the nature of such dispute. By not later than five (5) business days
after the recipient has received such notice of dispute, each party shall
have selected for itself a representative who shall have the authority to
bind such party, and shall additionally have advised the other party in
writing of the name and title of such representative. By not later than ten
(10) business days after the date of such notice of dispute, the party
against whom the dispute shall be raised shall select a mediation firm in the
Boston area and such representatives shall schedule a date with such firm for
a mediation hearing. The parties shall enter into good faith mediation and
shall share the costs equally. If the representatives of the parties have not
been able to resolve the dispute within fifteen (15) business days after such
mediation hearing, then any and all claims, disputes or controversies arising
under, out of, or in connection with this Agreement, including any dispute
relating to patent validity or infringement,

                                      -10-
<PAGE>   13
shall be resolved by final and binding arbitration in Boston, Massachusetts
under the rules of the American Arbitration Association, or the Patent
Arbitration Rules if applicable, then obtaining. The arbitrators shall have no
power to add to, subtract from or modify any of the terms or conditions of this
Agreement, nor to award punitive damages. Any award rendered in such
arbitration may be enforced by either party in either the courts of the
Commonwealth of Massachusetts or in the United States District Court for the
District of Massachusetts, to whose jurisdiction for such purposes M.I.T. and
LICENSEE each hereby irrevocably consents and submits.

     12.2  Notwithstanding the foregoing, nothing in this Article shall be
construed to waive any rights or timely performance of any obligations existing
under this Agreement.

                                13 - TERMINATION

     13.1  If LICENSEE shall cease to carry on its business, this Agreement
shall terminate upon notice by M.I.T.

     13.2  Should LICENSEE fail to make any payment whatsoever due and payable
to M.I.T. hereunder, M.I.T. shall have the right to terminate this Agreement
effective on thirty (30) days' notice, unless LICENSEE shall make all such
payments to M.I.T. within said thirty (30) day period. Upon the expiration of
the thirty (30) day period, if LICENSEE shall not have made all such payments
to M.I.T., the rights, privileges and license granted hereunder shall
automatically terminate.

     13.3  Upon any material breach or default of this Agreement by LICENSEE
(including, but not limited to, breach or default under Paragraph 3.3), other
than those occurrences set out in Paragraphs 13.1 and 13.2 hereinabove, which
shall always take precedence in that order over any material breach or default
referred to in this Paragraph 13.3, M.I.T. shall have the right to terminate
this Agreement and the rights, privileges and license granted hereunder
effective on ninety (90) days' notice to LICENSEE. Such termination shall become
automatically effective unless LICENSEE shall have cured any such material
breach or default prior to the expiration of the ninety (90) day period.

     13.4  LICENSEE shall have the right to terminate this Agreement at any
time on six (6) months' notice to M.I.T., and upon payment of all amounts due
M.I.T. through the effective date of the termination.

     13.5  Upon termination of this Agreement for any reason, nothing herein
shall be construed to release either party from any obligation that matured
prior to the effective date of such termination; and Articles
1,8,9,10,12,13.5,13.6 and 15 shall survive any such termination. LICENSEE and
any sublicensee thereof may, however, after the effective date of such
termination, sell all LICENSED PRODUCTS, and complete LICENSED PRODUCTS in the
process of manufacture at the time of such termination and sell the same,
provided that LICENSEE shall make

                                      -11-

<PAGE>   14
the payments to M.I.T. as required by Article 4 of this Agreement and shall
submit the reports required by Article 5 hereof.

     13.6  Upon termination of this Agreement for any reason, any sublicensee
not then in default shall have the right to seek a license from M.I.T. M.I.T.
agrees to negotiate such licenses in good faith under reasonable terms and
conditions.

                14 - PAYMENTS, NOTICES AND OTHER COMMUNICATIONS

     Any payments, notice or other communication pursuant to this Agreement
shall be sufficiently made or given on the date of mailing if sent to such party
by certified first class mail, return receipt requested, postage prepaid,
addressed to it at its address below or as it shall designate by written notice
given to the other party:

          In the case of M.I.T.:

          Director
          Technology Licensing Office
          Massachusetts Institute of Technology
          77 Massachusetts Avenue, Room E32-300
          Cambridge, Massachusetts 02139

          In the case of LICENSEE:

                         15 - MISCELLANEOUS PROVISIONS

     15.1  All disputes arising out of or related to this Agreement, or the
performance, enforcement, breach or termination hereof, and any remedies
relating thereto, shall be construed, governed, interpreted and applied in
accordance with the laws of the Commonwealth of Massachusetts, U.S.A., except
that questions affecting the construction and effect of any patent shall be
determined by the law of the country in which the patent shall have been
granted.

     15.2  The parties hereto acknowledge that this Agreement sets forth the
entire Agreement and understanding of the parties hereto as to the subject
matter hereof, and shall not be subject to any change or modification except by
the execution of a written instrument signed by the parties.

     15.3  The provisions of this Agreement are severable, and in the event
that any provisions of this Agreement shall be determined to be invalid or
unenforceable under any controlling body of the law, such invalidity or
unenforceability shall not in any way affect the validity or enforceability of
the remaining provisions hereof.

     15.4  LICENSEE agrees to mark the LICENSED PRODUCTS sold in the United
States with all applicable United States patent numbers. ALL LICENSED PRODUCTS
shipped to or sold

                                      -12-
<PAGE>   15
in other countries shall be marked in such a manner as to conform with the
patent laws and practice of the country of manufacture or sale.

     15.5  The failure of either party to assert a right hereunder or to insist
upon compliance with any term or condition of this Agreement shall not
constitute a waiver of that right or excuse a similar subsequent failure to
perform any such term or condition by the other party.

     IN WITNESS WHEREOF, the parties have duly executed this Agreement the day
and year set forth below.

MASSACHUSETTS INSTITUTE OF TECHNOLOGY    SANGAMO BIOSCIENCES, INC.

By /s/ Lita Nelsen                       By /s/ Edward O. Lanphier
  -------------------------------          -----------------------------
Name LITA L. NELSEN, DIRECTOR            Name EDWARD LANPHIER
    -----------------------------            ---------------------------
Title TECHNOLOGY LICENSING OFFICE        Title PRESIDENT
     ----------------------------             ---------------------------
Date April 17, 1996                      Date May 9, 1996
    -----------------------------            ---------------------------

                                      -13-
<PAGE>   16
                                FIRST AMENDMENT

This Amendment, with the effective date of 12/10/97, is to the License
Agreement dated May 9, 1996, between Sangamo Biosciences, Inc. and
Massachusetts Institute of Technology.

The parties thereto now further agree as follows:

1. Paragraph 1.7 shall be deleted, including the "Note", and replaced with the
following:

     1.7  "FIELDS OF USE" shall mean all fields of use.

2. Paragraph 2.4 shall be deleted and replaced with:

     2.4  LICENSEE and M.I.T. agree that neither party shall assert the Patent
     Rights against not-for-profit institutions in their conduct of research,
     provided, however, that if a not-for-profit institution practices under the
     Patent Rights to conduct high throughput drug screening on behalf of a
     commercial entity, then the Patent Rights may be asserted against that
     institution.

3. The following shall be inserted as Paragraph 3.4:

     3.4  After January 1, 2002, if M.I.T. notifies LICENSEE of a request by a
     third party for a license to the Patent Rights for an application or
     product (such as drug screening for a particular disease state, or
     development of a Licensed Product for a particular disease state) not
     currently under development by LICENSEE (or its sublicensee), and no such
     application or product (nor any directly competing application or product)
     is then currently under development or being sold by LICENSEE or a
     sublicensee, then LICENSEE shall either:

          (a)  within three months of the request submit to M.I.T. plans to
          begin development of the application or product within six months of
          the original request, at a level of effort appropriate to success of
          the development in a commercially reasonable time; or

          (b)  begin good faith negotiations with the third party toward
          granting a sublicense to the Patent Rights for the application
          or product.

     If LICENSEE does not begin (or abandons) efforts under (a) above, and does
     not reach a sublicense agreement with the third party within 6 months
     thereafter, M.I.T. shall have the right to grant a nonexclusive license to
     the Patent Rights to the third party for the particular application or
     product, under terms no more favorable to the third party than are granted
     hereunder to LICENSEE, and including diligent development milestones.
     M.I.T. shall share with LICENSEE two-thirds (66.7%) of any revenue it
     derives from such license.

4. Royalties:

<PAGE>   17
(a) LICENSEE shall pay to M.I.T. a First Amendment Issue Fee of
              *                due upon              *              .

(b) The License Maintenance Fees due under P. 4.1b shall be increased to
*              on January 1, 1998 and               *               per year
beginning January 1, 1999 and beyond.

(c) Subparagraphs 4.1e and 4.1g shall be deleted.

(d) The sublicense fees of P. 4.1h shall be increased to            * per
sublicense granted plus               *               per year per sublicense.

(e) The following subparagraph shall be added to P. 4.1, and shall be designated
as subparagraph P. 4.1i

     4.1i:       *        OF ANY MILESTONE FEES OR ROYALTIES PAID TO LICENSEE
FROM SUBLICENSEES OR OTHER THIRD PARTIES FOR PRODUCTS DISCOVERED OR DEVELOPED
THROUGH THE USE OF LICENSED PRODUCTS OR LICENSED PROCESSES. HOWEVER, IF THESE
MILESTONE FEES AND ROYALTIES ARE ON PRODUCTS WHOSE COMPOSITION AND/OR PRODUCTION
ARE COVERED BY OTHER PATENTS OWNED OR CONTROLLED BY LICENSEE, AND IF THESE FEES
AND ROYALTIES ARE ALSO INTENDED TO COMPRISE COMPENSATION FOR PRACTICE UNDER SUCH
LICENSEE PATENTS, THEN THE PAYMENTS DUE TO M.I.T. SHALL BE          * OF THE
MILESTONE FEES AND ROYALTIES.

Agreed to for:

MASSACHUSETTS INSTITUTE OF TECHNOLOGY    SANGAMO BIOSCIENCES, INC.

By /s/ Lita Nelsen                       By /s/ Edward O. Lanphier
  -------------------------------          -----------------------------
Name LITA L. NELSEN, DIRECTOR            Name EDWARD LANPHIER
    -----------------------------            ---------------------------
Title  TECHNOLOGY LICENSING OFFICE       Title PRESIDENT & CEO
     ----------------------------             ---------------------------
Date Dec 1, 1997                         Date  12/10/97
    -----------------------------            ---------------------------

* Certain information on this page has been omitted and filed separately with
  the Commission. Confidential treatment has been requested with respect to the
  omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}]]